Picture of Amgen logo

AMGN Amgen Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Annual cashflow statement for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-KPRESS
Standards:
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line5,8936,5526,7174,090
Depreciation
Deferred Taxes
Non-Cash Items1,6171,683-560671
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-1,194-733-4842,3659,958
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities9,2619,7218,47111,4909,958
Capital Expenditures-880-936-1,112-1,096-1,858
Purchase of Fixed Assets
Other Investing Cash Flow Items1,613-5,108-25,09250-85
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities733-6,044-26,204-1,046-1,943
Financing Cash Flow Items-78-103-72-124-10,859
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-8,271-4,03721,048-9,415-10,859
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash1,723-3603,3151,029-2,844